Document is current
Any future updates will be listed below
-
Authors
Joseph, Adrien https://orcid.org/0000-0002-5278-8966
Chen, Hui
Anagnostopoulos, Gerasimos https://orcid.org/0000-0002-2042-8675
Montégut, Léa
Lafarge, Antoine https://orcid.org/0000-0002-2481-5728
Motiño, Omar https://orcid.org/0000-0002-3858-0966
Castedo, Maria
Maiuri, Maria Chiara https://orcid.org/0000-0001-9760-7674
Clément, Karine
Terrisse, Safae
Martin, Anne Laure
Vaz-Luis, Ines
Andre, Fabrice
Grundler, Franziska
de Toledo, Françoise Wilhelmi
Madeo, Frank
Zitvogel, Laurence https://orcid.org/0000-0003-1596-0998
Goldwasser, François
Blanchet, Benoit
Fumeron, Frédéric https://orcid.org/0000-0002-7916-4619
Roussel, Ronan
Martins, Isabelle
Kroemer, Guido https://orcid.org/0000-0002-9334-4405
- License Information
-
More Information
Article History
Received: 29 March 2021
Revised: 5 May 2021
Accepted: 17 May 2021
First Online: 9 June 2021
Ethical approval
: All patients provided written informed consent, in compliance with French and German laws and the principles of the revised Declaration of Helsinki. Each study was approved by the local ethics committee.
: G.K. has filed patent application dealing with targeting the ACBP/DBI system in anorexia, obesity, and co-morbidities, as well as patent applications dealing with caloric restriction mimetics (autophagy inducers) for the treatment of aging, age-related diseases, cancer, obesity, and co-morbidities. G.K. is a scientific co-founder of everImmune, Samsara Therapeutics and Therafast Bio. F.M. is confounder of Samsara Therapeutics and Longevity Labs. All the others authors declare no competing interests.
